Syndax Pharmaceuticals, Inc. (SNDX)
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. The company is known for its use of epigenetic modulators, particularly histone deacetylase (HDAC) inhibitors, to enhance the effectiveness of immunotherapies and targeted treatments. Syndax's lead investigational drug, Axzagertib (formerly Entinostat), aims to improve outcomes in various cancers by modulating the tumor microenvironment and overcoming resistance mechanisms.
Company News
Syndax Pharmaceuticals will report its Q2 2025 financial results and host a conference call on August 4, 2025, providing an update on its innovative cancer therapies and ongoing clinical trials.
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
Within the last quarter, Syndax Pharmaceuticals (NASDAQ:SNDX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 5 3 0 0 0 In the last 3 months, 11 analysts have offered 12-month price targets for Syndax Pharmaceuticals. The company has an average price target of $36.82 with a high of $42.00 and a low of $30.00. Below is a summary of how these 11 analysts rated Syndax Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, ...Full story available on Benzinga.com
Shares of SmileDirectClub, Syndax Pharmaceuticals, AMC and Chinese automakers were most active ahead of Monday's market open.
Syndax’s lead product candidates include SNDX-5613 and SNDX-6352. Click here to read about its growth prospects and my recommendation.